Clinical Trials Browser

Has results × Afatinib × Thoracic × Clear all

NCT02191891 2025-06-25

Xentuzumab (BI 836845) Plus Afatinib in Patients With Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC)

Phase 1 Completed

32 enrolled 14 charts

Carcinoma, Non-Small-Cell Lung

NCT01853826 2025-04-11

An Open Label Trial of Afatinib (Giotrif) in Treatment-naive (1st Line) or Chemotherapy Pre-treated Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Harboring EGFR Mutation(s)

Phase 3 Completed

481 enrolled 8 charts

Carcinoma, Non-Small-Cell Lung

NCT05834348 2025-03-30

DELINOR

5,279 enrolled 10 charts

Carcinoma, Non-Small-Cell Lung

NCT04206787 2025-02-28

The Study Observes Afatinib as First-line Treatment in Patients With Epidermal Growth Factor Receptor (EGFR) Mutation-positive Advanced Non-small Cell Lung Cancer

72 enrolled 12 charts

Carcinoma, Non-Small-Cell Lung

NCT02597946 2025-02-19

Afatinib in NSCLC With HER2 Mutation

Phase 2 Completed

18 enrolled 12 charts

Carcinoma, Non-Small-Cell Lung

NCT04795245 2024-12-27

Non-interventional Study for Real-world Data of Afatinib Treatment in First-line Setting and of Subsequent Therapies for Patients With Advanced Epidermal Growth Factor Receptor (EGFR) Mutation-positive Lung Adenocarcinoma

805 enrolled 13 charts

Carcinoma, Non-Small-Cell Lung

NCT02364609 2024-10-16

Pembrolizumab and Afatinib in Patients With Non-small Cell Lung Cancer With Resistance to Erlotinib

Phase 1 Completed

11 enrolled 12 charts

Carcinoma, Non-Small-Cell Lung

NCT04750824 2024-09-19

Real-World Effectiveness of Afatinib (Gilotrif) Following Immunotherapy in the Treatment of Metastatic, Squamous Cell Carcinoma of the Lung: A Multi-Site Retrospective Chart Review Study in the U.S.

110 enrolled 24 charts

Carcinoma, Non-Small-Cell Lung

NCT02795156 2023-12-05

Study Assessing Activity of Molecularly Matched Targeted Therapies in Select Tumor Types Based on Genomic Alterations

Phase 2 Completed

100 enrolled 14 charts

GenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell

NCT04179890 2023-05-25

UpSwinG

462 enrolled 23 charts

Carcinoma, Non-Small-Cell Lung

NCT02440854 2022-04-27

Evaluate the Impact of Afatinib on Quality of Life and Symptom Burden of Greek Subjects With Advanced NSCLC in Routine Patient Care Settings

80 enrolled 37 charts

Carcinoma, Non-Small-Cell Lung

NCT04552535 2022-01-11

A Study in the United States Using Electronic Medical Records (EMR) to Assess Effectiveness of Afatinib (Gilotrif) Following Pembrolizumab and Chemotherapy in the Treatment of Metastatic Squamous Cell Carcinoma of the Lung

200 enrolled 18 charts

Squamous Non-small Cell Lung Cancer

NCT03370770 2020-12-24

Afatinib Osimertinib Sequencing NIS

204 enrolled 10 charts

Carcinoma, Non-Small-Cell Lung

NCT01999985 2020-11-27

Phase I Trial of Afatinib (BIBW 2992) and Dasatinib in Non-small Cell Lung Cancer (NSCLC)

Phase 1 Completed

25 enrolled 10 charts

Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, Lung Diseases, Lung Neoplasms, Neoplasms, Neoplasms by Site, Pleural Diseases, Pleural Effusion, Pleural Neoplasms, Respiratory Tract Diseases, Respiratory Tract Neoplasms, Thoracic Neoplasms, Pleural Effusion, Malignant

NCT01466660 2020-04-07

LUX-Lung 7: A Phase IIb Trial of Afatinib(BIBW2992) Versus Gefitinib for the Treatment of 1st Line EGFR Mutation Positive Adenocarcinoma of the Lung

Phase 2 Completed

319 enrolled 19 charts

Lung Neoplasms

NCT02514174 2020-03-30

Afatinib Treatment for Patients With EGFR Mutation Positive NSCLC Who Are Age 70 or Older

Phase 4 Completed

25 enrolled 13 charts

Carcinoma, Non-Small-Cell Lung

NCT02047903 2020-01-09

GIOTRIF in First Line Therapy of Advanced NSCLC With EGFR-mutations

161 enrolled 15 charts

Carcinoma, Non-Small-Cell Lung

NCT01953913 2019-08-12

Afatinib (BIBW 2992) in Advanced Non-Small Cell Lung Cancer Patients With EGFR Mutation

Phase 3 Completed

542 enrolled 11 charts

Carcinoma, Non-Small-Cell Lung

NCT02271906 2019-04-30

The ATTAIN Study: A Therapeutic Trial of Afatinib In the Neoadjuvant Setting

Phase 2 Terminated

2 enrolled 8 charts

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Lung Neoplasms

NCT01523587 2019-02-15

LUX-Lung 8: A Phase III Trial of Afatinib (BIBW 2992) Versus Erlotinib for the Treatment of Squamous Cell Lung Cancer After at Least One Prior Platinum Based Chemotherapy

Phase 3 Completed

795 enrolled 17 charts

Carcinoma, Non-Small-Cell Lung

NCT02208843 2018-12-17

Afatinib as Second-line Therapy for Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Mutation

Phase 4 Completed

60 enrolled 10 charts

Carcinoma, Non-Small-Cell Lung

NCT01121393 2018-12-14

BIBW 2992 (Afatinib) vs Gemcitabine-cisplatin in 1st Line Non-small Cell Lung Cancer (NSCLC)

Phase 3 Completed

364 enrolled 28 charts 1 FDA

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung

NCT02131259 2018-09-07

Long-term Observation PMS for Afatinib

1,605 enrolled 7 charts

Carcinoma, Non-Small-Cell Lung

NCT00949650 2018-04-06

BIBW 2992 (Afatinib) Versus Chemotherapy as First Line Treatment in NSCLC With EGFR Mutation

Phase 3 Completed

345 enrolled 23 charts 1 FDA

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung

NCT01074177 2018-03-09

Understanding Mechanisms of Acquired Resistance to BIBW2992

Phase NA Completed

24 enrolled 10 charts

Carcinoma, Non-Small-Cell Lung

NCT02695290 2017-09-18

Afatinib in EGFR+NSCLC (Recurrent or Stage IV) - Patients With Poor Performance Status (ECOG 2 or 3)

Phase 4 Terminated

1 enrolled 3 charts

Carcinoma, Non-Small-Cell Lung

NCT02044380 2017-03-31

Afatinib in Patients With Non Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Mutations

Phase 3 Completed

14 enrolled 6 charts

Carcinoma, Non-Small-Cell Lung

NCT01814553 2016-10-31

ADAM-Afatinib Diarrhea Assessment and Management

Phase 3 Completed

40 enrolled 10 charts

Carcinoma, Non-Small-Cell Lung

NCT00525148 2016-09-16

LUX Lung 2 Phase II Single Arm BIBW 2992 "Afatinib" in NSCLC With EGFR Activating Mutations

Phase 2 Completed

129 enrolled 18 charts 1 FDA

Carcinoma, Non-Small-Cell Lung

NCT00656136 2016-07-26

BIBW 2992 and BSC Versus Placebo and BSC in Non-small Cell Lung Cancer Patients Failing Erlotinib or Gefitinib (LUX-LUNG 1)

Phase 3 Completed

585 enrolled 12 charts

Carcinoma, Non-Small-Cell Lung

NCT01090011 2015-10-02

Trial of BIBW 2992 (Afatinib) + Cetuximab in Non-Small Cell Lung Cancer

Phase 1 Completed

171 enrolled 23 charts

Carcinoma, Non-Small-Cell Lung

NCT00711594 2015-01-15

LUX-Lung 4: BIBW 2992 (Afatinib) Phase I Trial in Advanced Non Small Cell Lung Cancer Patients & Phase II Trial in Non Small Cell Lung Cancer Patients Failing Erlotinib or Gefitinib

Phase 2 Completed

74 enrolled 23 charts

Carcinoma, Non-Small-Cell Lung

NCT00730925 2014-03-26

Single-arm Trial of BIBW 2992 (Afatinib) in Demographically and Genotypically Selected NSCLC Patients

Phase 2 Completed

41 enrolled 9 charts

Carcinoma, Non-Small-Cell Lung

NCT01003899 2013-12-31

A Phase II Trial of Afatinib(BIBW 2992) in Third-line Treatment for Patients With Stage IIIB/IV Adenocarcinoma of the Lung Harbouring Wild-type Epidermal Growth Factor Receptor[EGFR]

Phase 2 Completed

43 enrolled 8 charts

Carcinoma, Non-Small-Cell Lung